X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Strides Arcolab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs STRIDES SHASUN LTD - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

STRIDES SHASUN LTD 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA STRIDES SHASUN LTD SANOFI INDIA/
STRIDES SHASUN LTD
 
P/E (TTM) x 39.1 39.6 98.6% View Chart
P/BV x 8.4 1.0 856.2% View Chart
Dividend Yield % 1.1 1.0 106.4%  

Financials

 SANOFI INDIA   STRIDES SHASUN LTD
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
STRIDES SHASUN LTD
Mar-17
SANOFI INDIA/
STRIDES SHASUN LTD
5-Yr Chart
Click to enlarge
High Rs4,5601,275 357.7%   
Low Rs4,400918 479.3%   
Sales per share (Unadj.) Rs1,028.5389.6 264.0%  
Earnings per share (Unadj.) Rs129.028.0 461.1%  
Cash flow per share (Unadj.) Rs186.048.9 380.3%  
Dividends per share (Unadj.) Rs68.004.50 1,511.1%  
Dividend yield (eoy) %1.50.4 369.8%  
Book value per share (Unadj.) Rs753.6303.1 248.6%  
Shares outstanding (eoy) m23.0389.42 25.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.42.8 154.8%   
Avg P/E ratio x34.739.2 88.6%  
P/CF ratio (eoy) x24.122.4 107.4%  
Price / Book Value ratio x5.93.6 164.4%  
Dividend payout %52.716.1 327.7%   
Avg Mkt Cap Rs m103,17498,036 105.2%   
No. of employees `0003.65.8 62.5%   
Total wages/salary Rs m3,5925,881 61.1%   
Avg. sales/employee Rs Th6,537.76,005.9 108.9%   
Avg. wages/employee Rs Th991.41,014.0 97.8%   
Avg. net profit/employee Rs Th819.8431.2 190.1%   
INCOME DATA
Net Sales Rs m23,68634,834 68.0%  
Other income Rs m7081,686 42.0%   
Total revenues Rs m24,39436,520 66.8%   
Gross profit Rs m5,2816,428 82.2%  
Depreciation Rs m1,3131,872 70.2%   
Interest Rs m152,269 0.7%   
Profit before tax Rs m4,6613,973 117.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m04 0.0%   
Extraordinary Inc (Exp) Rs m0-1,006 0.0%   
Tax Rs m1,691470 359.8%   
Profit after tax Rs m2,9702,501 118.8%  
Gross profit margin %22.318.5 120.8%  
Effective tax rate %36.311.8 306.7%   
Net profit margin %12.57.2 174.7%  
BALANCE SHEET DATA
Current assets Rs m15,67338,165 41.1%   
Current liabilities Rs m6,67830,402 22.0%   
Net working cap to sales %38.022.3 170.4%  
Current ratio x2.31.3 187.0%  
Inventory Days Days7677 98.3%  
Debtors Days Days22104 21.4%  
Net fixed assets Rs m8,09837,639 21.5%   
Share capital Rs m230894 25.8%   
"Free" reserves Rs m17,08826,210 65.2%   
Net worth Rs m17,35627,105 64.0%   
Long term debt Rs m016,377 0.0%   
Total assets Rs m25,40081,168 31.3%  
Interest coverage x311.72.8 11,332.6%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.90.4 217.3%   
Return on assets %11.85.9 200.0%  
Return on equity %17.19.2 185.5%  
Return on capital %26.912.1 223.6%  
Exports to sales %24.50-   
Imports to sales %28.00-   
Exports (fob) Rs m5,801NA-   
Imports (cif) Rs m6,627NA-   
Fx inflow Rs m7,14513,465 53.1%   
Fx outflow Rs m6,8464,076 168.0%   
Net fx Rs m2999,389 3.2%   
CASH FLOW
From Operations Rs m3,2262,881 112.0%  
From Investments Rs m-1,555-7,051 22.1%  
From Financial Activity Rs m-1,8183,382 -53.8%  
Net Cashflow Rs m-147-788 18.7%  

Share Holding

Indian Promoters % 0.0 27.7 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 37.8 38.1%  
FIIs % 14.6 8.6 169.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 25.9 40.5%  
Shareholders   15,184 56,241 27.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   TORRENT PHARMA  ALKEM LABORATORIES  AJANTA PHARMA  PFIZER  ALEMBIC PHARMA  

Compare SANOFI INDIA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Extends Gains; Vedanta & Yes Bank Lead the Rally(12:30 pm)

Stock markets in India are trading higher taking cues from their Asian peers, which rebounded today following a strong lead in Wall Street.

Related Views on News

STRIDES SHASUN LTD Announces Quarterly Results (1QFY19); Net Profit Down 57.5% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, STRIDES SHASUN LTD has posted a net profit of Rs 38 m (down 57.5% YoY). Sales on the other hand came in at Rs 7 bn (down 21.2% YoY). Read on for a complete analysis of STRIDES SHASUN LTD's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Banks are Raising FD Rates and That's Good News(Vivek Kaul's Diary)

Aug 7, 2018

Lending to the retail segment remains strong, whereas lending to the service sector has picked up dramatically.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Aug 17, 2018 02:51 PM

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 5-YR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS